Is the FDA taking inconsistent approaches to Duchenne drugs? And how will a new batch of drug executives shake up their companies? Find out on the latest episode of "The…
Is the Food and Drug Administration taking inconsistent approaches to Duchenne muscular dystrophy drugs? How will a new batch of drug executives shake up their companies? And why is Adam talking to a recruiter?
We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.
Lire l’article complet sur le site source
STAT News - Sante & Medecine (EN)